Editas Medicine Reports Q3 2025 Results and Advances EDIT-401 Toward Human Trials

Editas Medicine Inc. reported its third quarter 2025 financial results and provided business updates. The company highlighted preclinical proof-of-concept data presented at the American Heart Association (AHA) and the European Society of Gene and Cell Therapy (ESGCT), demonstrating that its lead candidate, EDIT-401, achieved over 90% reduction in LDL cholesterol levels in non-human primates. In mouse models, the LDL-C reduction was maintained over a three-month study, supporting the durability of the effect. Editas Medicine remains on track to submit an investigational new drug (IND) or clinical trial application (CTA) for EDIT-401 by mid-2026, with initial human proof-of-concept data anticipated by year-end 2026. The company has extended its cash runway into the third quarter of 2027 through proceeds from sales of its common stock under its at-the-market facility and continued financial discipline. Editas also announced participation in the 8th Annual Evercore Healthcare Conference on December 2, 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here